Glaukos Corporation (NYSE:GKOS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Glaukos Corporation (NYSE:GKOS) have been given an average rating of “Moderate Buy” by the sixteen ratings firms that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $132.5385.

A number of equities analysts have issued reports on GKOS shares. BTIG Research boosted their price objective on shares of Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their price target on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. UBS Group upped their price target on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Citigroup lifted their price objective on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Wells Fargo & Company boosted their target price on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 19,340 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the completion of the sale, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. This trade represents a 17.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Thomas William Burns sold 186,945 shares of Glaukos stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the sale, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 329,655 shares of company stock worth $37,752,234. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GKOS. Smartleaf Asset Management LLC raised its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares in the last quarter. CWM LLC increased its holdings in shares of Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares during the last quarter. Evergreen Capital Management LLC raised its position in shares of Glaukos by 4.3% during the 4th quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 145 shares in the last quarter. UMB Bank n.a. raised its position in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares in the last quarter. Finally, Park Place Capital Corp lifted its holdings in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 4.5%

Shares of Glaukos stock opened at $124.04 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos has a 52-week low of $73.16 and a 52-week high of $161.78. The company’s 50 day moving average price is $112.34 and its 200-day moving average price is $96.59. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of -80.55 and a beta of 0.67.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm’s revenue was up 38.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.28) EPS. Equities research analysts forecast that Glaukos will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.